Amritsar Online

MiRNA Sequencing and Assay Market Revenue to Cross $ 468.99 Million by 2027: The Insight Partners

 Breaking News
  • No posts were found

MiRNA Sequencing and Assay Market Revenue to Cross $ 468.99 Million by 2027: The Insight Partners

November 24
21:31 2021
MiRNA Sequencing and Assay Market Revenue to Cross $ 468.99 Million by 2027: The Insight Partners
The growth of the miRNA sequencing and assay market is mainly attributed to the widening range of miRNA applications and rise in funding for genomics research. However, the challenges related to delivery, efficacy, and specificity of miRNA-based therapeutics may hinder the market growth.

According to The Insight Partners new research study on “miRNA Sequencing and Assay Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Product, Technology, and End User, the market is expected to reach US$ 468.99 million by 2027 from US$ 192.31 million in 2019; it is estimated to grow at a CAGR of 11.9% from 2020 to 2027. The report highlights trends prevailing in the miRNA sequencing and assay market along with the factors governing its growth.

Strategic Insights:

Report Coverage             

(Details)

Market Size Value in      

(US$ 192.31 million in 2019)

Market Size Value by    

(US$ 468.99 million by 2027)

Growth Rate     

(CAGR of 11.9% from 2020 to 2027)

Forecast Period

(2020- 2027)

Base Year           

(2020)

No. of Pages     

(156)

No. Tables          

(65)

Segments covered         

(By Product, Technology End User and Geography)

Regional scope 

(North America; Europe; Asia Pacific; Latin America; MEA)

Country scope  

(US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina)

Report coverage             

(Revenue forecast, company ranking, competitive landscape, growth factors, and trends)

Get Sample PDF Copy of MiRNA Sequencing and Assay Market at: https://www.theinsightpartners.com/sample/TIPRE00006960/

miRNA is a small non-coding RNA molecule of 20–30-nucleotide length, and it plays an important role in gene regulation. As it is partially complementary to messenger RNA (mRNA), it serves a major function of down-regulating the gene expression, which makes it a key controller of important cellular functions. miRNAs are associated with pathological processes such as viral infections, autoimmune diseases, and carcinogenesis. Thus, extensive research is being conducted to identify new miRNAs. The growth of the miRNA sequencing and assay market is mainly attributed to the factors such widening range of miRNA applications and rise in funding for genomics research. However, challenges related to delivery, efficacy, and specificity of miRNA-based therapeutics is projected to deter the market growth.

Widening Range of MicroRNA Applications

miRNAs are a group of non-coding and small RNA molecules of 20–30-nucleotide length. These molecules bind to a target messenger RNA (mRNA) and lead to gene silencing, thereby controlling gene expression. Thus, they play a critical role in cell physiology and development. miRNAs regulate all cellular functions such as cell proliferation, differentiation, and apoptosis. Being involved in the process of differentiation, they play a crucial role in offering tissue identity. Hence, miRNAs are thought to be a useful marker in identifying cell types.

Further, miRNAs are also associated with pathological processes such as viral infections, autoimmune diseases, and carcinogenesis. A few of them can act as oncogenes (oncomiRs), while several other act as tumor suppressor miRNAs. The altered expression of miRNAs is correlated with the occurrence of different types of cancer. The potential of miRNAs, combined with next-generation sequencing technologies, as a new class of cancer biomarkers is being explored. They are predicted to have a vital role to play in assessing development, progression, prognosis, diagnosis, and treatment of cancer. Moreover, several classes of miRNAs have also emerged as promising biomarkers for infectious diseases caused by pathogens, including HIV, Hendra virus, tuberculosis, and malaria.

Furthermore, discovery regarding the role of miRNAs in disease development have made miRNAs a key target of novel therapeutic approaches. Several miRNA-targeted therapeutics against the diseases such as cancer and hepatitis have reached the clinical phase. For instance, Santaris Pharma has developed a therapeutic molecule named Miravirsen that targets miR-122 for the treatment of hepatitis C virus (HCV) infection; the molecule is in the Phase II clinical trial. Therefore, the growing range of applications of miRNAs is driving the growth of the miRNA sequencing and assay market.

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns.

Download the Latest COVID-19 Analysis on MiRNA Sequencing and Assay Market Growth Research Report at: https://www.theinsightpartners.com/covid-analysis-sample/TIPRE00006960

The miRNA sequencing and assay market, by product, is segmented into library preparation and consumables. The consumables segment held a larger share of the market in 2019, whereas the library preparation segment is anticipated to register a higher CAGR in the market during the forecast period.

Based on technology, the miRNA sequencing and assay market is segmented into sequencing by synthesis, nanopore, and ion semiconductor sequencing. The sequencing by synthesis segment held the largest share of the market in 2019; however, the nanopore segment is expected to register the highest CAGR in the market during 2020–2027.

MiRNA Sequencing and Assay Market: Competitive Landscape and Key Developments

Illumina, Inc., Thermo Fisher Scientific Inc., Qiagen, Perkin Elmer, Inc., Takara Bio Inc., New England Biolabs, Norgen Biotek Corp, TriLink BioTechnologies Inc, Lexogen GmbH, and Oxford Nanopore Technologies are among the leading companies operating in the miRNA sequencing and assay market.

Order a Copy of MiRNA Sequencing and Assay Market Shares, Strategies and Forecasts 2021-2028 Research Report at: https://www.theinsightpartners.com/buy/TIPRE00006960/

Collaboration is one of the major strategies adopted by the miRNA sequencing and assay market players to enlarge customer base worldwide, which also permits them to maintain their brand name globally.

Browse Related Reports and get Sample copy

MiRNA Tools and Services Market Forecast to 2028 – Covid-19 Impact and Global Analysis – By Product and Services (Research Tools, Services); Technology (Extraction Tools, qRT-PCR, NGS, Microarray, Others); End User (Research and Academic Institutes, Biotechnology Companies, Other End Users) and Geography

MiRNA Kits Market Forecast to 2028 – COVID-19 Impact and Global Analysis by Product Type (Synthesis Kit- s, Isolation Kits, Others); End users/Applications (Research and Academic Institutes, Pharma and Biotech Companies, CROs, Others)

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Research Study – https://liverpoolstudentmedia.com/author/theinsightpartners/

Media Contact
Company Name: The Insight Partners
Contact Person: Sameer Joshi
Email: Send Email
Phone: +1-646-491-9876
City: Pune
State: Maharashtra
Country: India
Website: https://www.theinsightpartners.com/pr/mirna-sequencing-and-assay-market

Related Articles

Recent Posts

U.S. EVCI Market Demand To Escalate Noticeably With 39% CAGR, Due To Rising Government Support To Propel Adoption of Electric Vehicle Till 2025 | Million Insights

Read Full Article